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Edited by Richard MaraisAbstract The Ser/Thr kinase Akt1 is activated by growth
factors subsequent to its phosphorylation on Thr308 and
Ser473. In the present study, Akt1 was found to be constitutively
modiﬁed with O-GlcNAc. Treatment of SH-SY5Y cells with
O(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenyl-
carbamate (PUGNAc), which inhibits the enzymatic removal of
O-GlcNAc from proteins, increased cytosolic O-GlcNAc-Akt1
levels. Treatment of cells with insulin-like growth factor-1
(IGF-1) also increased O-GlcNAc-Akt1 levels and increased
Akt1 phosphorylation. PUGNAc treatment did not attenuate
IGF-1 induced Akt1 phosphorylation. These results indicate that
Akt1 can be simultaneously modiﬁed with O-GlcNAc and
phosphorylated. However, PUGNAc induced the nuclear accu-
mulation of Akt1 suggesting that the O-GlcNAc-modiﬁcation
on Akt1 may play a role in Akt1 nuclear localization.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The serine/threonine kinase Akt1 (protein kinase B) aﬀects a
broad range of cell functions. Activation of Akt1 increases glu-
cose transport, regulates gene transcription, and promotes cell
survival in the face of lethal conditions (reviewed extensively in
[1–3]). Akt1 is activated by a variety of stimuli including
growth factors such as insulin-like growth factor-1 (IGF-1)
and hormones such as insulin [3,4]. Stimulation with IGF-1
activates phosphatidylinositol-3 kinase signaling which results
in the dual phosphorylation of Akt1 on Thr308 and Ser473
and maximally increases Akt1 activity [5]. One well known
substrate for Akt1 is glycogen synthase kinase-3b (GSK3b).
Akt1 phosphorylates Ser9 of GSK3b which inhibits GSK3b
activity [6].
Akt1 is predominantly in the cytosol of unstimulated cells
[7,8], but subsequent to activation by IGF-1 a fraction ofAbbreviations: O-GlcNAc, O-linked b-N-acetylglucosamine; O-GlcN-
Acase, N-acetyl-b-D-glucosaminidase; GSK3b, glycogen synthase
kinase-3b; HBP, hexosamine biosynthetic pathway; b-hex, b-N-ace-
tyl-hexosaminidase; IGF-1, insulin-like growth factor-1; PNGase F,
peptide N-glycosidase F; PUGNAc, O(2-acetamido-2-deoxy-D-gluco-
pyranosylidene)amino-N-phenylcarbamate
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doi:10.1016/j.febslet.2006.04.051Akt1 accumulates in the nucleus [9,10]. However, compared
to the rapid phosphorylation of Thr308 and Ser473 and activa-
tion of Akt1, which is evident within 3 min of IGF-1 treatment
[8,9], Akt1 nuclear accumulation occurs relatively slowly with
maximal nuclear accumulation of Akt1 occurring after 20 min
of IGF-1 treatment [9,10]. The mechanism responsible for
Akt1 nuclear transport is unclear.
Numerous proteins have recently been found to be post-
translationally modiﬁed with O-linked b-N-acetylglucosamine
(O-GlcNAc) moieties. The O-GlcNAc-modiﬁcation can aﬀect
several biochemical processes including signal transduction,
protein localization, and protein–protein interactions [11,12].
O-GlcNAc-modiﬁcation of proteins occurs enzymatically
when a single GlcNAc unit is covalently attached to Ser
and Thr residues on cytosolic and nuclear proteins [13],
and on some proteins O-GlcNAc occurs reciprocal to phos-
phorylation on the same Ser-Thr sites [13]. The source of
GlcNAc for the O-GlcNAc-modiﬁcation is the hexosamine
biosynthetic pathway (HBP), with one of the end products
of the HBP being UDP-GlcNAc [14], the donor sugar nucle-
otide for O-GlcNAc. Thus, increased glucose ﬂux through
the HBP can contribute to increased levels of O-GlcNAc-
modiﬁed proteins. Accumulation of O-GlcNAc-modiﬁed
proteins can also be achieved by inhibition of N-acetyl-b-D-
glucosaminidase (O-GlcNAcase), the enzyme which catalyzes
the removal of O-GlcNAc from proteins [15]. O(2-acetam-
ido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate
(PUGNAc) potently and selectively inhibits O-GlcNAcase
[15–17], and has become a valuable tool for the identiﬁcation
of O-GlcNAc-modiﬁed proteins. It is unknown if Akt1 is di-
rectly modiﬁed with O-GlcNAc, and if this modiﬁcation af-
fects IGF-1-induced Akt signaling. The present study shows
that in SH-SY5Y neuroblastoma cells a subfraction of cyto-
solic Akt1 is constitutively modiﬁed with O-GlcNAc, and
PUGNAc treatment increased the level of O-GlcNAc-modi-
ﬁed Akt1 in the cytosol and caused the accumulation of
Akt1 in the nucleus.2. Materials and methods
2.1. Cell culture
SH-SY5Y neuroblastoma cells were cultured in RPMI 1640 medium
as previously described [8]. Cells were plated at a density of 105 cells/
60 mm dish and were cultured for 48 h prior to treatments. Adherent
cells were rinsed twice with serum-free media supplemented with
2 mM L-glutamine, 100 U/ml penicillin and 100 lg/ml streptomycin
and were cultured in serum-free media for 24 h prior to treatmentsblished by Elsevier B.V. All rights reserved.
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supplemented with 5% fetal bovine serum, 100 lg/ml penicillin, and
100 lg/ml streptomycin (Gibco-Invitrogen).2.2. Detection of glycosylated Akt1 with wheat germ agglutinin-
conjugated beads
Cytosolic and nuclear extracts were prepared as described previously
[18]. Cells were lysed in 100 ll lysis buﬀer (10 mM Tris, pH 7.5, 10 mM
NaCl, 3 mMMgCl, 0.05% NP-40, 1 mM EGTA, 1 mM sodium ortho-
vanadate, 50 mM sodium ﬂuoride, 100 mM PMSF, 10 lg/ml leupep-
tin, 10 lg/ml aprotinin, 5 lg/ml pepstatin A, 1 nM okadaic acid, and
50 lM PUGNAc (Toronto Research Chemicals)). Protein concentra-
tions were determined using the bicinchoninic acid method (Pierce).
Purity of the nuclear and cytosolic samples was determined by immu-
noblotting the two fractions with antibodies for the compartment-spe-
ciﬁc proteins tubulin (Sigma) a cytosolic protein and histone
(Chemicon) a nuclear protein.
To detect O-glycosylation of Akt1, 50 lg of cytosolic protein in a
total volume of 100 ll lysis buﬀer was ﬁrst precleared with 30 ll of
50% v/v of unconjugated agarose beads for 2 h at 4 C to eliminate
non-speciﬁc interactions of proteins with the agarose beads. The aga-
rose beads were collected by centrifuging in a microcentrifuge
(20817 · g, 1 min). The supernatant was transferred to a new reaction
tube and incubated with 30 ll of 50% v/v wheat germ agglutinin
(WGA)-conjugated agarose beads (Vector Laboratories) for 20 h at
4 C. The WGA-conjugated agarose beads were collected by centrifu-
gation and the supernatant was saved to measure the amount of
unbound Akt1. The unconjugated agarose beads and the WGA-
conjugated agarose beads were washed three times in lysis buﬀer
and mixed with 30 ll of Laemmli sample buﬀer, and placed in a boil-
ing waterbath for 5 min. To determine the amount of unbound Akt1,
the protein concentration was measured in the saved supernatant and
1 lg of protein was mixed with 30 ll of Laemmli sample buﬀer, boiled,
and loaded onto a 7.5% SDS–polyacrylamide gel in parallel with the
eluted proteins from the unconjugated beads and the WGA-conju-
gated beads. Proteins were immunoblotted as previously described
[8] with Akt1 antibody (Sigma). Cytosolic extracts were also immuno-
blotted with antibodies for pThr308Akt, pSer473Akt, pSer9GSK3b
(Cell Signaling), O-GlcNAc (RL2) (Aﬃnity Bioreagents), GSKb
(BD Biosciences).
For peptide N-glycosidase F (PNGase F) (New England BioLabs)
treatment, cells were lysed in 50 mM sodium phosphate buﬀer, pH
7.5, containing 0.05% NP-40, and protease inhibitors. The cytosolic ex-
tracts (100 lg of protein) were incubated with 20 units of PNGase F
for 20 h in a 37 C waterbath. The extracts were assayed for O-Glc-
NAc-modiﬁcation using the WGA-conjugated beads as described
above. For b-N-acetyl-hexosaminidase (b-hex) (New England Bio-
Labs) treatments, cytosolic extracts were incubated with WGA-conju-
gated beads as described above, then incubated with 10 units of b-hex
in 50 mM sodium citrate buﬀer, pH 4.5, for 2 h in a 37 C waterbath.
The beads were washed and the eluted proteins were immunoblotted
for Akt1. A 10 ll aliquot from samples incubated under identical con-
ditions without the glycosidases were immunoblotted for Akt1 to ver-
ify that proteolysis of Akt1 had not occurred under these conditions.
To disrupt protein complexes that may contribute to Akt1 association
with WGA, cytosolic extracts were incubated with WGA-conjugated
agarose beads in the presence of 0.3% SDS, and eluted proteins were
immunoblotted for Akt1.
2.3. Measurement of Akt1 activity
Akt1 activity was measured using a non-radioactive Akt kinase as-
say kit (Cell Signaling) with some minor modiﬁcations. Brieﬂy,
100 lg of cytosolic extracts were immunoprecipitated with 3.5 lg of
Akt1 antibody in lysis buﬀer for 18 h at 4 C. The immobilized im-
mune complexes were washed three times with 500 ll lysis buﬀer
and washed twice with 500 ll kinase buﬀer (25 mM Tris, pH 7.5,
5 mM b-glycerophosphate, 2 mM DTT, 0.1 mM sodium orthovana-
date, and 10 mM MgCl2). The immune complexes were resuspended
in 50 ll of kinase buﬀer containing 0.2 mM ATP and 1 lg of GSK3
fusion protein substrate. The reaction was incubated in a 30 C water
bath for 30 min. The reaction was stopped by the addition of SDS
sample buﬀer followed immediately by boiling for 5 min. The samples
were loaded onto a 12% SDS–polyacrylamide gel, transferred onto
nitrocellulose and immunoblotted with a GSK3a/b-phospho-speciﬁcantibody to evaluate Akt1 activity. The blot was then stripped and
reblotted with the Akt1 antibody to determine eﬃciency of immuno-
precipitation.
2.4. Cell transfections
To express wild-type Akt (wtAkt) and mutated Akt (DDAkt),
HEK293 cells (5 · 105 cells) were transfected in 35 mm dishes in
DMEM/F-12 media supplemented with 1% fetal bovine serum,
100 lg/ml penicillin, and 100 lg/ml streptomycin (Gibco-Invitrogen)
at 37C. After achieving approximately 70% growth conﬂuency, each
dish was transfected with 2 lg of either wtAKT or DDAKT plasmids
using Fugene6 (Roche Diagnostics Corporation) according to manu-
facturer’s instructions. After 24 h post-transfection, the cells were har-
vested as described previously.2.5. Immunoﬂuorescence
Cells were immunoﬂuorescently labeled as described previously [18].
Cells cultured on poly-D-lysine-coated glass coverslips were treated
with PUGNAc (50 lM, 30 min). The cells were washed with PBS
and then ﬁxed and permeabilized in cold methanol–acetone (1:1) for
10 min at 20 C. The coverslips were washed twice with PBS and
blocked with 2% BSA in PBS for 2 h. The coverslips were incubated
with Akt1 antibody (28 lg/ml) for 18 h at 4 C. The coverslips were
thoroughly washed with PBS and incubated for 1 h at room tempera-
ture with 10 lg/ml ﬂuorescein isothiocyanate-conjugated anti-mouse
antibody (Jackson Immunoresearch). The coverslips were washed
thoroughly with PBS and incubated with 1 ng/ml Hoechst 33342 for
10 min at room temperature. The coverslips were washed with PBS
and a ﬁnal rinse with water, and mounted onto glass coverslips and
examined by a ﬂuorescence microscope (Nikon) set at 400· magniﬁca-
tion.3. Results
To examine the O-GlcNAc-modiﬁcation of Akt1, cells were
lysed and the cytosolic extract (50 lg of protein input) was
incubated with either unconjugated agarose beads or WGA-
conjugated agarose beads. WGA-conjugated agarose beads
bind O-GlcNAc-modiﬁed proteins with high aﬃnity [19].
Akt1 binding to WGA was clearly evident (Fig. 1A) while only
minimal non-speciﬁc binding of Akt1 was seen on the control
unconjugated agarose beads. Abundant Akt1 was detected in a
1 lg sample of the unbound proteins (UB), indicating that a
large fraction of the cytosolic Akt1 is not constitutively mod-
iﬁed with GlcNAc. For all subsequent experiments the cyto-
solic extracts were ﬁrst precleared with unconjugated beads.
To test if the glucose concentration in the media impacts
Akt1 glycosylation, cells were cultured in glucose-free media
for 24 h, then treated with 20 mM glucose for 1 h. This re-
sulted in a marked increase in the WGA binding of Akt1
(Fig. 1B), indicating that Akt1 glycosylation is aﬀected by glu-
cose content in the media. Changes in glucose concentration
however did not aﬀect basal or IGF-1-induced Akt1 phosphor-
ylation at Thr308 and Ser473 (data not shown).
WGA binds terminal GlcNAc residues, thus several methods
were used to determine if the Akt1 binding to WGA was med-
iated by O-GlcNAc. Lysates were incubated with excess PNG-
ase F, which removes N-linked GlcNAc [20]. PNGase F
treatment did not aﬀect Akt1 binding to WGA (Fig. 1C) how-
ever incubation with b-N-acetylhexosaminidase (b-hex), which
removes terminal O-linked glycosidic modiﬁcations [21], mark-
edly decreased Akt1 binding to WGA. Thus the WGA-Akt1
interaction is due primarily to O-GlcNAc on Akt1. To test if
b-hex treatment aﬀected Akt1 phosphorylation, cells were trea-
ted with and without IGF-1 (50 ng/ml, 30 min) and Akt1 was
Fig. 1. Akt1 is modiﬁed with O-GlcNAc. (A) Cytosolic extracts
from SH-SY5Y cells were incubated with either unconjugated
agarose beads or WGA-conjugated agarose beads. The proteins
bound to the unconjugated agarose beads (beads) and WGA-
conjugated agarose beads (WGA) were eluted by boiling, and
together with the unbound proteins (UB) were immunoblotted with
Akt1 antibody. (B) SH-SY5Y cells were cultured in glucose-free
media for 24 h, then treated with 20 mM glucose for 1 h. Cytosolic
extracts were analyzed for O-GlcNAc-modiﬁcation of Akt1 using
WGA-conjugated agarose beads and cytosolic extracts were immu-
noblotted for total levels of Akt1. (C) Cytosolic extracts (100 lg of
protein) were incubated with 20 units of PNGase F for 20 h in a
37 C waterbath, and then incubated with WGA-conjugated beads.
For b-N-acetyl-hexosaminidase (b-hex) treatments, cytosolic extracts
were incubated with WGA-conjugated beads as described above,
then incubated with 10 units of b-hex for 2 h in a 37 C waterbath.
The eluted proteins were immunoblotted for Akt1. An aliquot from
samples without the glycosidases were immunoblotted for Akt1 to
verify that proteolysis of Akt1 had not occurred under these
conditions. To conﬁrm that b-hex did not aﬀect Akt1 phosphory-
lation, Akt1 was immunoprecipitated from 100 lg of cytosolic
extracts from cells treated with and without IGF-1 (50 ng/ml,
30 min), then incubated in the absence and presence of b-hex, and
then immunoblotted with pSer473Akt antibody. The blot was
stripped and then reblotted with Akt1 antibody. (D) Cells were
treated with 50 lM PUGNAc for 45 min and cytosolic extracts were
analyzed for O-GlcNAc-modiﬁcation of Akt1 using WGA-conju-
gated beads. Protein complexes were disrupted by the addition of
0.3% SDS during the incubation of the cytosolic extracts with the
WGA-conjugated agarose beads. The eluted proteins were immu-
noblotted for Akt1.
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cipitated Akt1 was reacted in the absence or presence of b-hex
and then immunoblotted for pSer473. b-hex treatment did not
aﬀect basal or IGF-1-induced Akt1 Ser473 phosphorylation
(Fig. 1C), nor did it aﬀect Akt1 Thr308 phosphorylation (data
not shown). Thus, b-hex treatment selectively removed Akt O-
glycosylation.
To further establish O-GlcNAc-modiﬁcation of Akt1, cells
were treated with PUGNAc (50 lM for 45 min) to increase
the level of O-GlcNAc-modiﬁed proteins. PUGNAc treatment
resulted in a marked increase in Akt1 binding to WGA
(Fig. 1D). To conﬁrm that the precipitation of Akt1 with
WGA was due to O-GlcNAc on Akt1 and not due to an O-gly-
cosylated Akt1-binding protein, cytosolic extracts were incu-
bated with WGA in the presence of 0.3% SDS, a method to
disrupt protein complexes which has been used previously
for O-GlcNAc analysis [22]. The presence of SDS did not pre-
vent Akt1 binding to WGA and it did not aﬀect the PUGNAc-
mediated increase in Akt1 binding to WGA. Thus, the binding
of Akt1 to WGA is due to a direct interaction between Akt1
and WGA and not due to an intermediary O-glycosylated pro-
tein bound to Akt1. Total cytosolic Akt1 levels were not in-
creased with PUGNAc treatment indicating that PUGNAc
did not aﬀect Akt1 synthesis or stability. Taken together, these
results show that a limited pool of cytosolic Akt1 is constitu-
tively modiﬁed with O-GlcNAc and that the O-GlcNAc-mod-
iﬁcation of Akt1 is dynamic.
The eﬀects of PUGNAc treatment on Akt1 O-GlcNAc-mod-
iﬁcation and Akt1 phosphorylation were tested. Cells were
time-dependently (0–60 min) treated with PUGNAc and cyto-
solic extracts were immunoblotted with an antibody, RL2, that
detects O-GlcNAc on proteins. PUGNAc treatment caused an
overall increase in the level O-GlcNAc-modiﬁed proteins in the
cytosol (Fig. 2A) and increased O-GlcNAc-modiﬁcation of
Akt1 as early as 15 min following PUGNAc treatment
(Fig. 2B). Maximum, 203% of control, Akt1 O-GlcNAc-mod-
iﬁcation occurred after 30 min of PUGNAc treatment, and
this level was maintained after 60 min of PUGNAc treatment.
There was little or no decrease in basal Akt1 phosphorylation
at Thr308 and Ser473 following PUGNAc treatment, and
PUGNAc did not decrease basal Akt1 activity (Fig. 2C). Thus,
O-GlcNAc-modiﬁcation of Akt1 did not attenuate any of the
activity-associated indices of Akt1.
IGF-1 potently induces phosphorylation of Akt1 at Thr308
and Ser473. The eﬀect of IGF-1 treatment was tested on Akt1
phosphorylation and O-GlcNAc-modiﬁcation. IGF-1 treat-
ment resulted in a robust and rapid increase in Thr308 and
Ser473 phosphorylation of Akt1 (Fig. 2B). Maximum phos-
phorylation occurred in less than 15 min of IGF-1 treatment
and remained at maximum level for the entire 60 min IGF-1
time course. Interestingly, IGF-1 treatment also time-depen-
dently increased O-GlcNAc on several cytosolic proteins
(Fig. 2A) and also increased Akt1 binding to WGA
(Fig. 2B), indicating that a subfraction of Akt1 is modiﬁed
with O-GlcNAc following IGF-1 stimulation. Compared to
Akt1 phosphorylation the increase in O-GlcNAc-modiﬁcation
of Akt1 was markedly delayed. O-GlcNAc-modiﬁed Akt1 level
increased after 15 min of IGF-1 treatment to 135% of control.
Maximum O-GlcNAc-modiﬁed Akt1 was seen between 30
and 45 min of IGF-1 treatment (198% and 206%, respectively,
of control). Thus, IGF-1 treatment caused both robust
Fig. 2. PUGNAc and IGF-1 increase cytosolic O-GlcNAc levels and O-GlcNAc-modiﬁcation of Akt1. (A) SH-SY5Y cells were time-dependently
treated with 50 lMPUGNAc and 50 ng/ml IGF-1 for the indicated times. Cytosolic extracts were immunoblotted for O-GlcNAc with RL2 antibody.
(B) Cytosolic extracts from PUGNAc and IGF-1 treated cells were incubated with WGA-conjugated beads for analysis of O-GlcNAc-modiﬁcation
of Akt1. O-GlcNAc modiﬁed Akt1 bands were quantitated by scanning densitometry. Means ± S.E., n = three experiments; *P < 0.05 (ANOVA)
compared to values from untreated cells. Cytosolic extracts were immunoblotted with pThr308Akt1, pSer473Akt, and Akt1 antibodies. (C) For
measurement of Akt1 activity, cells were time-dependently treated with 50 lM PUGNAc or treated with IGF-1 (50 ng/ml, 30 min). The cytosolic
extracts were immunoprecipitated with Akt1 antibody and incubated with GSK3 fusion protein substrate. The reaction mixture was immunoblotted
with a GSK3 phospho-speciﬁc antibody. To determine eﬃciency of immunoprecipitation the blot was stripped and reblotted with Akt1 antibody.
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of O-GlcNAc-modiﬁed Akt1.
In the next set of experiments the relationship betweenO-Glc-
NAc-modiﬁcation and phosphorylation of Akt1 was investi-
gated. Cytosolic extracts from control and IGF-1-treated cells
were incubated with WGA. The WGA-bound proteins were
eluted and immunoblotted with pThr308 and pSer473Akt anti-
bodies. Large increases in Thr308 and Ser473 phosphorylation
were seen on the WGA-bound Akt1 compared to the total level
of boundAkt1 (Fig. 3A), indicating that nearly all of the O-Glc-
NAc-modiﬁed Akt1 is also phosphorylated on Thr308 and
Ser473. To further conﬁrm if Akt1 is phosphorylated and mod-iﬁed with O-GlcNAc simultaneously, HEK293 cells were tran-
siently transfected with wild-type (wt) Akt and with a mutant,
constitutively active Akt with both Thr308 and Ser473 mutated
to Asp (DD). These mutations mimic phosphorylation at these
sites. Both the wtAkt and DDAkt were tagged with hemagglu-
tinin (HA) to diﬀerentiate between the expressed Akt and
endogenous Akt1. Cytosolic extracts from the transfected cells
were incubated with WGA-conjugated beads and the eluted
proteins were immunoblotted with HA antibody. Both the
wtAkt and DDAkt boundWGA equally well (Fig. 3B), indicat-
ing that Akt1 can be modiﬁed with O-GlcNAc and phosphory-
lated on Thr308 and Ser473 simultaneously.
Fig. 3. Akt1 can be simultaneously modiﬁed with O-GlcNAc and phosphorylated on Thr308 and Ser473. (A) SH-SY5Y cells were stimulated with
50 ng/ml IGF-1 for 30 min. Cytosolic extracts were incubated with WGA-conjugated agarose beads, and the eluted proteins were immunoblotted
with pThr308Akt1, pSer473Akt1, and Akt1 antibodies. (B) HEK293 cells were transiently transfected with wild-type HA-tagged Akt1 or an HA-
tagged Akt1 mutant in which the Thr308 and Ser473 were dually mutated to Asp (DDAkt). Cytosolic extracts were incubated with WGA-conjugated
agarose beads and eluted proteins were immunoblotted with HA antibody. (C) SH-SY5Y cells were treated with 50 lM PUGNAc 30 min prior to
treatment with IGF-1 (50 ng/ml, 30 min). Cytosolic extracts were immunoblotted with pThr308Akt1, pSer473Akt1, Akt1, pSer9GSK3b, and GSK3b
antibodies. (D) Cells were treated with 20 lM LY294002 30 min prior to treatment with 50 ng/ml IGF-1 for 30 min or 50 lM PUGNAc for 30 min.
Cytosolic extracts were incubated with WGA-conjugated beads for analysis of O-GlcNAc-modiﬁcation of Akt1, and cytosolic extracts from IGF-1
and LY294002-treated cells were also immunoblotted for pThr308Akt and Akt1.
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the insulin-induced phosphorylation at Thr308 of Akt1 and
Ser9 of GSK3b [23]. We wanted to determine if an elevation
of O-GlcNAc levels by PUGNAc would also block IGF-1-
mediated Akt1 signaling, thus the eﬀect of PUGNAc treatment
on IGF-1-induced Akt1 and GSK3b phosphorylation was
tested. Cells were treated with PUGNAc 30 min prior to treat-
ment with IGF-1 for 30 min. PUGNAc treatment did not
cause any deﬁcits in Akt1 Thr308 and Ser473 phosphorylation,
and Ser9 phosphorylation of GSK3b (Fig. 3C). Thus, unlike
the reported detrimental eﬀects of PUGNAc on insulin-in-
duced Akt1 signaling [23], in the present study PUGNAc treat-
ment did not attenuate IGF-1-induced Akt1 signaling.
IGF-1 induces the activation of PI3K signaling. Since IGF-1
treatment was found to increase O-GlcNAc-modiﬁcation of
Akt1, the eﬀect of the PI3K inhibitor LY294002 was tested
on IGF-1-induced Akt1 O-glycosylation. IGF-1 treatment in-
creased Akt1 O-glycosylation (Fig. 3D) which was mostly
blocked by pretreatment of cells with LY294002 prior to stim-
ulation with IGF-1. The blockade of IGF-1-induced Akt1 O-
GlcNAc-modiﬁcation corresponded with the inhibition of
Akt1 phosphorylation at Thr308. By comparison, O-Glc-
NAc-modiﬁcation of Akt1 by PUGNAc treatment was inde-
pendent of PI3K signaling (Fig. 3D), as LY294002
pretreatment did not block PUGNAc-induced Akt1 O-glyco-sylation. Thus, IGF-1-induced Akt1 O-glycosylation is depen-
dent on activation of PI3K signaling.
Because it has been suggested that O-GlcNAc may play a
role in nuclear localization of proteins [24] we tested the
possibility that PUGNAc treatment would lead to a redistri-
bution of Akt1 in the nucleus. PUGNAc treatment time-
dependently increased Akt1 nuclear accumulation within
15 min of PUGNAc treatment (Fig. 4A) and marked accu-
mulations of Akt1 in the nucleus were evident 30 and
60 min following PUGNAc treatment. In addition, immuno-
ﬂuorescence staining of Akt1 revealed that little Akt1 was
detectable within the nucleus in control cells (Fig. 4C), but
increased nuclear staining of Akt1 as well as perinuclear
staining of Akt1 was evident following PUGNAc treatment.
PUGNAc did not increase the nuclear levels of GSK3b
(Fig. 4A), a protein which also shuttles into the nucleus
[18], indicating that PUGNAc did not elicit a generalized
accumulation of proteins into the nucleus. The level of his-
tone, a resident nuclear protein, was not altered by PUGNAc
treatment. Tubulin, a highly abundant cytosolic protein was
not evident in the nuclear fraction (Fig. 4B), indicating that
the nuclear extract was essentially devoid of contaminating
cytosolic proteins. Thus, at least one functional outcome of
increased O-GlcNAc levels on Akt1 signaling is the facilita-
tion of Akt1 entry into the nucleus.
Fig. 4. PUGNAc induces nuclear accumulation of Akt1. (A) SH-SY5Y cells were treated with 50 lM PUGNAc for the indicated times. Nuclear and
cytosolic extracts were immunoblotted with Akt1 antibody and nuclear extracts with histone antibody and GSK3b antibody. (B) Complete
separation of the cytosolic and nuclear fractions was conﬁrmed by immunoblotting the cytosolic and nuclear extracts with tubulin and histone
antibodies. (C) Control and PUGNAc-treated (50 lM, 30 min) cells were immunoﬂuorescently labeled with Akt1-ﬂuorescein isothiocyanate-
conjugated antibody, upper panels. Nuclei were stained with Hoechst 33342, lower panels.
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Much interest has recently focused on identifying proteins in
the PI3K/Akt signaling pathway that are modiﬁed with O-Glc-
NAc, because an elevation of O-GlcNAc-modiﬁed proteins
has been associated with insulin resistance partially due to ma-
jor defects in PI3K/Akt signaling [23,25]. Although several
proteins upstream of Akt have been shown to be modiﬁed with
O-GlcNAc, O-GlcNAc-modiﬁcation of Akt1 has not been re-
ported. In the present study the role of O-GlcNAc on IGF-1-
induced Akt1 signaling was examined. A subfraction of the
cytosolic pool of Akt1 was found to be constitutively modiﬁed
with O-GlcNAc. In addition, treatment of cells with the selec-
tive O-GlcNAcase inhibitor PUGNAc and treatment with
IGF-1 signiﬁcantly increased O-GlcNAc-modiﬁcation of the
cytosolic subfraction of Akt1. Thus, this is the ﬁrst demonstra-
tion that a portion of the cytosolic Akt1 is dynamically mod-
iﬁed with O-GlcNAc.
WGA is commonly used for the separation of O-GlcNAc-
modiﬁed proteins. Since WGA binds any terminal GlcNAc
residue, several methods were used to conﬁrm that Akt1 bears
the O-GlcNAc-modiﬁcation [26]. Akt1 binding to WGA was
markedly reduced after incubation with b-hex but not with
PNGase F. Treatment of cells with PUGNAc increased Akt1
binding to WGA, and the dissociation of protein complexeswith SDS did not disrupt PUGNAc-induced Akt1 binding to
WGA. Together, these results indicate that Akt1 is subject to
modiﬁcation by O-GlcNAc. Several antibodies have been
developed which recognize O-GlcNAc moieties, but these anti-
bodies, and WGA, have inherent limitations [27]. For example,
proteins such as GSK3b can be modiﬁed with O-GlcNAc
in vitro [28], however the O-GlcNAc-modiﬁcation of GSK3b
was below the threshold of detection by an O-GlcNAc-speciﬁc
antibody [23]. O-GlcNAc antibodies were also evaluated for
the detection of O-GlcNAc on Akt1 with mixed results (data
not shown). Thus, the WGA lectin-based method may be more
useful for analysis of the O-GlcNAc-modiﬁcation of Akt1.
In the present study the ramiﬁcation of increased O-GlcNAc
on IGF-1-induced Akt1 signaling was examined. Elevations
in O-GlcNAc levels by PUGNAc treatment did not aﬀect
basal Akt1 phosphorylation at Thr308 and Ser473, alter basal
Akt1 activity, or result in the attenuation of IGF-1-induced
Akt1 signaling. Surprisingly, IGF-1 treatment itself increased
the levels of O-GlcNAc-modiﬁed proteins in the cytosol, in-
creased the level of O-GlcNAc-modiﬁed Akt1, and robustly
activated Akt1. The Akt1 bound to WGA was also found to
be highly phosphorylated on Thr308 and Ser473 following
IGF-1 stimulation, and an Akt1 mutant devoid of the
Thr308 and Ser473 sites bound WGA equivalently well as
the wild-type Akt1. Furthermore, IGF-1-induced Akt1 O-gly-
J.C. Gandy et al. / FEBS Letters 580 (2006) 3051–3058 3057cosylation was blocked by LY294002 indicating the depen-
dence of IGF-1-induced Akt1 O-glycosylation on PI3K signal-
ing. Thus, these observations indicate that Akt1 can be
simultaneously modiﬁed with O-GlcNAc and phosphorylated
on Thr308 and Ser473. A high glucose concentration was also
found to substantially increase the level of O-GlcNAc-modi-
ﬁed Akt1, however decreases in basal Akt1 phosphorylation,
or attenuation of IGF-1 signaling under hyperglycemic condi-
tions were not observed (data not shown). The reported eﬀects
of PUGNAc on insulin-induced Akt signaling are mixed. For
example, Vosseller et al. [23] reported that treatment of 3T3-L1
adipocytes with 100 lM PUGNAc for 16 h resulted in insulin
resistance due to increased O-GlcNAc-modiﬁcation of proteins
and the partial blockade of insulin-induced Akt phosphoryla-
tion at Thr308. A concomitant decrease in Ser9 phosphoryla-
tion of GSK3b was also reported. Conversely, Arias et al.
[29] found that treatment of rat skeletal muscle tissue with
100 lmol/L of PUGNAc for 19 h did not result in any notice-
able diminution of insulin-induced phosphorylations at
Thr308 and Ser473 of Akt or Ser9 of GSK3b, although insulin
resistance and O-GlcNAc-modiﬁcation of proteins was evi-
dent. Mechanistically speaking, insulin and IGF-1 activate
PI3K/Akt1 signaling in essentially the same manner. In the
present study acute treatment of 50 lM PUGNAc, total expo-
sure time of 60 min, did not impede the full IGF-1-induced
activation of Akt1, in concordance with Arias et al. using insu-
lin [29]. However we cannot rule out the possibility that greater
accumulations of O-GlcNAc-modiﬁed proteins and O-Glc-
NAc-Akt1 may occur by chronic PUGNAc treatment which
could deleteriously aﬀect Akt1 signaling.
Having shown that Akt1 is modiﬁed with O-GlcNAc, the
potential eﬀect of this modiﬁcation on the nuclear distribution
of Akt1 was examined, as there is some evidence to suggest
that O-GlcNAc may function as a signal for nuclear transport
[24]. Akt1 is known to enter the nucleus subsequent to its acti-
vation. Interestingly, PUGNAc treatment was found to in-
crease the level of Akt1 in the nucleus independent of
phosphorylation of Thr308 and Ser473. The elevation in the
nuclear level of Akt1 paralleled the increase in O-GlcNAc-
modiﬁed Akt1 by PUGNAc. These results must be interpreted
with caution because the mechanisms underlying Akt1 nuclear
translocation remain unclear. Akt1 has been shown to increase
in the nucleus subsequent to its phosphorylation at Thr308
[10], and by a process which requires the binding of Akt1 with
the protein product of the TCL1 oncogene [30]. Thus, it is pos-
sible that the O-GlcNAc moiety on Akt1 may directly increase
Akt1 binding to the nuclear pore complex, as indicated by the
perinuclear staining of Akt1 following PUGNAc treatment
(Fig. 4C), to facilitate the entry of Akt1 into the nucleus, or
the O-GlcNAc-modiﬁcation may increase the association of
Akt1 with a nuclear transport protein.
It has been widely speculated that Akt1 is modiﬁed with O-
GlcNAc, but this has never been reported, until now. We have
shown that a subfraction of Akt1 is constitutively and dynam-
ically modiﬁed with O-GlcNAc. Further investigations will be
necessary to determine the sites on Akt1 modiﬁed with O-Glc-
NAc, the eﬀects of O-GlcNAc on Akt1 function, and its role in
Akt1 nuclear transport.
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